Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma

Yang,Wei; Wang,Xiaoyuan; Zheng,Wei; Li,Kedong; Liu,Haofeng; Sun,Yueming

doi:10.3892/ijo.2012.1741

Genetic and epigenetic alterations are involved in the regulation of TPM1 in cholangiocarcinoma

Authors:
- Wei Yang
- Xiaoyuan Wang
- Wei Zheng
- Kedong Li
- Haofeng Liu
- Yueming Sun
View Affiliations

Affiliations: Department of Minimally Invasive Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, P.R. China
Published online on: December 17, 2012 https://doi.org/10.3892/ijo.2012.1741
Pages: 690-698

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma is a malignant tumor originating from biliary epithelial cells. The tumor suppressor gene tropomyosin 1 (TPM1) is downregulated in several human cancer types; however, its expression status in cholangiocarcinoma is still unknown. We elucidated TPM1 expression and its regulation mechanism in cholangiocarcinoma. Real-time (RT)-PCR, western blot analysis and immunohistochemistry were performed to examine TPM1 expression levels in cholangiocarcinoma cell lines and tumor tissues. Cell lines were treated with lentiviral vector containing the miR-21 knockdown and inhibitors of genetic and epigenetic mechanisms (manumycin A, LY294002, U0126, DAC and TSA), and the TPM1 expression change was observed by RT-PCR and western blot analyses. Cell proliferation, apoptosis and migration were evaluated by water-soluble tetrazolium salt (WST-1) assay, flow cytometry and wound healing experiments, respectively. TPM1 was downregulated in the intrahepatic cholangiocarcinoma cells (HuCCT1) and upregulated in the extrahepatic cholangiocarcinoma cells (QBC939) compared with normal intrahepatic biliary epithelial cells (HIBEC). TPM1 stained negative in the intrahepatic cholangiocarcinoma tissues, as revealed by immunohistochemistry, although there was no significant difference in staining of the intrahepatic cholangiocarcinoma tissues and adjacent non-cancer tissues. RAS and two important downstream signaling pathways (RAS/PI3K/AKT and RAS/MEK/ERK) were involved in TPM1 regulation and inhibition of the epigenetic mechanisms such as DNA methylation, histone deacetylation and miR-21 upregulation upregulated TPM1 expression. Inhibitors of genetic and epigenetic mechanisms (manumycin A, LY294002, U0126, DAC and TSA) inhibited cell proliferation and migration and induced apoptosis. These data indicated that TPM1 is downregulated in HuCCT1 cells and that the Ras signaling pathway as well as DNA methylation, histone deacetylation and miR-21 upregulation play important roles in the suppression of TPM1 expression in HuCCT1 cells. Thus, compounds that inhibit genetic and epigenetic mechanisms may be promising agents in treating cholangiocarcinoma.

View Figures

View References

1.	Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1304. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Hong K and Geschwind JF: Locoregional: intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol. 37:110–117. 2010. View Article : Google Scholar : PubMed/NCBI
3.	Ramage JK, Donaghy A, Farrant JM, Iorns R and Williams R: Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterology. 108:865–869. 1995. View Article : Google Scholar : PubMed/NCBI
4.	Schevzov G, Whittaker SP, Fath T, Lin JJ and Gunning PW: Tropomyosin isoforms and reagents. Bioarchitecture. 1:135–164. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Lin JJ, Warren KS, Wamboldt DD, Wang T and Lin JL: Tropomyosin isoforms in non-muscle cells. Int Rev Cytol. 170:1–38. 1997. View Article : Google Scholar
6.	Bharadwaj S and Prasad L: Tropomyosin-1, a novel suppressor of cellular transformation is downregulated by promoter methylation in cancer cells. Cancer Lett. 183:205–213. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Raval GN, Bharadwaj S, Levine EA, Willingham MC, Geary RL, Kute T and Prasad GL: Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene. 22:6194–6203. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Pawlak G, McGarvey TW, Nguyen TB, Tomaszewski JE, Puthiyaveettil R, Malkowicz SB and Helfman DM: Alterations in tropomyosin isoform expression in human transitional cell carcinoma of the urinary bladder. Int J Cancer. 110:368–373. 2004. View Article : Google Scholar : PubMed/NCBI
9.	Yager ML, Hughes JA, Lovicu FJ, Gunning PW, Weinberger RP and O’Neill GM: Functional analysis of the actin binding protein, tropomyosin 1, in neuroblastoma. Br J Cancer. 89:860–863. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Choi C, Kim D, Kim S, Jeong S, Song E and Helfman DM: From skeletal muscle to cancer: insights learned elucidating the function of tropomyosin. J Struct Biol. 177:63–69. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Mahadev K, Raval G, Bharadwaj S, et al: Suppression of the transformed phenotype of breast cancer by tropomyosin-1. Exp Cell Res. 279:40–51. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Bakin AV, Safina A, Rinehart C, Daroqui C, Darbary H and Helfman DM: A critical role of tropomyosins in TGF-beta regulation of the actin cytoskeleton and cell motility in epithelial cells. Mol Biol Cell. 15:4682–4694. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Xu RF, Sun JP, Zhang SR, et al: KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. Biomed Pharmacother. 65:22–26. 2011. View Article : Google Scholar : PubMed/NCBI
14.	O’Dell MR, Huang JL, Whitney-Miller CL, et al: Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res. 15:1557–1567. 2012.PubMed/NCBI
15.	Imai M and Takahashi N: Growth inhibition and mechanism of action of p-dodecylaminophenol against refractory human pancreatic cancer and cholangiocarcinoma. Bioorg Med Chem. 20:2520–2526. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Jinawath A, Akiyama Y, Sripa B and Yuasa Y: Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. J Cancer Res Clin Oncol. 133:271–278. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Hara M, Akasaka K, Akinaga S, et al: Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA. 90:2281–2285. 1993. View Article : Google Scholar : PubMed/NCBI
18.	Nagase T, Kawata S, Tamura S, et al: Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation. Int J Cancer. 65:620–626. 1996. View Article : Google Scholar : PubMed/NCBI
19.	Kainuma O, Asano T, Hasegawa M, Kenmochi T, Nakagohri T, Tokoro Y and Isono K: Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. Pancreas. 15:379–383. 1997. View Article : Google Scholar : PubMed/NCBI
20.	Ito T, Kawata S, Tamura S, et al: Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor. Jpn J Cancer Res. 87:113–116. 1996. View Article : Google Scholar : PubMed/NCBI
21.	Shields JM, Mehta H, Pruitt K and Der CJ: Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin. Mol Cell Biol. 22:2304–2317. 2002. View Article : Google Scholar
22.	Varga AE, Stourman NV, Zheng Q, et al: Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Oncogene. 24:5043–5052. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Liu S, Ren S, Howell P, Fodstad O and Riker AI: Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res. 21:545–558. 2008. View Article : Google Scholar : PubMed/NCBI
24.	Kawahigashi Y, Mishima T, Mizuguchi Y, et al: MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. J Nihon Med Sch. 76:188–197. 2009. View Article : Google Scholar
25.	Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI
27.	Li J, Huang H, Sun L, et al: MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res. 15:3998–4008. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Li T, Li D, Sha J, Sun P and Huang Y: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 383:280–285. 2009. View Article : Google Scholar : PubMed/NCBI
29.	Dong CG, Wu WK, Feng SY, Wang XJ, Shao JF and Qiao J: Co-inhibition of microRNA-10b and microRNA-21 exerts synergistic inhibition on the proliferation and invasion of human glioma cells. Int J Oncol. 41:1005–1012. 2012.PubMed/NCBI
30.	Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW and Baba HA: AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol. 13:6470–6477. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Leelawat K, Leelawat S, Narong S and Hongeng S: Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion. World J Gastroenterol. 13:1561–1568. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S and Tungpradubkul S: Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int. 9:32009. View Article : Google Scholar : PubMed/NCBI
33.	Menakongka A and Suthiphongchai T: Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol. 16:713–722. 2010. View Article : Google Scholar : PubMed/NCBI
34.	Wu T, Leng J, Han C and Demetris AJ: The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 3:299–307. 2004.PubMed/NCBI
35.	Matsumoto K, Nagahara T, Okano J and Murawaki Y: The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases. Oncol Rep. 20:863–872. 2008.PubMed/NCBI
36.	Liu XF, Jiang H, Zhang CS, Yu SP, Wang ZQ and Su HL: Targeted drug regulation on methylation of p53-BAX mitochondrial apoptosis pathway affects the growth of cholangiocarcinoma cells. J Int Med Res. 40:67–75. 2012. View Article : Google Scholar : PubMed/NCBI
37.	Xu LN, Wang X and Zou SQ: Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World J Gastroenterol. 14:2578–2581. 2008. View Article : Google Scholar : PubMed/NCBI
38.	Yin P, Zhao C, Li Z, et al: Sp1 is involved in regulation of cystathionine gamma-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines. Cell Signal. 24:1229–1240. 2012. View Article : Google Scholar : PubMed/NCBI
39.	Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, Lai MK and Lin JY: Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis. 32:138–145. 2011. View Article : Google Scholar : PubMed/NCBI
40.	Meng F, Henson R, Lang M, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell line. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
41.	Wehbe H, Henson R, Meng F, Mize-Berge J and Patel T: Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res. 66:10517–10524. 2006. View Article : Google Scholar : PubMed/NCBI